Unicycive Therapeutics (UNCY) Stock Forecast & Price Target

Unicycive Therapeutics is supported by a de-risked regulatory path for OLC, as the FDA’s prior CRLs cited manufacturing issues rather than clinical efficacy or safety, and the September 29, 2026 NDA resubmission with a new third-party vendor and clean NAI-inspected facility improves visibility on approval. The company’s balance sheet also looks sufficient, with $61.4M in cash and securities and runway into 2027, while the resubmission could still support an end-of-1Q27 action date and potentially a faster timeline if the original vendor passes inspection. Fundamentally, the setup is attractive because TDAPA could make OLC the only phosphate binder paid outside the ESRD bundle through mid-2029, creating a meaningful commercial tailwind if approval arrives as expected.

Unicycive Therapeutics is a clinical-stage biotech with no product revenue and a long record of operating losses, leaving valuation highly dependent on a single OLC approval and launch that still faces binary FDA, manufacturing, label-breadth, and reimbursement risks. Its financial profile is also fragile: about $61M in cash at the end of 2Q 2026, commitments for $102M through warrant tranches, and the possibility of additional capital raises before profitability is expected on a continuing basis until 2027, all of which heighten dilution risk. Even if approved, slower-than-expected dialysis contract wins, restricted formulary access, and competition from generic sevelamer, Fosrenol, and other binders could materially limit uptake and undermine projected revenues through 2031.